Published in:
Open Access 01-12-2014 | Meeting abstract
Metabolic syndrome: new therapeutic approaches
Published in: Italian Journal of Pediatrics | Special Issue 1/2014
Login to get accessExcerpt
In the last three decades in the United States the prevalence of overweight/obesity in pediatric population has more than tripled, causing the onset also in pediatric age of diseases previously considered exclusively of adults, such as metabolic syndrome (MetS) [1]. MetS represents a cluster of cardiometabolic abnormalities, including visceral obesity, dyslipidemia, hypertension and diabetes mellitus type 2 (T2DM) (Table 1). The prevalence of pediatric MetS ranged from 2% to 9% in the general population and from 12% to 44% in obese children, depending of definition used [1]. Several evidences suggest that the metabolic derangements observed in children may have a worrisome repercussion early on their health in adulthood [2, 3].
Table 1
Diagnostic criteria for metabolic syndrome in children and adolescents
|
IDF criteria
|
|||
|---|---|---|---|
|
Age (years)
|
6-9
|
10-15
|
>15 (adult criteria)
|
|
Waist circumference
|
≥90th percentile for age (MS as entity is not diagnosed)
|
≥90th percentile or adult cut-off if lower
|
≥94 cm for males,
≥80 cm for females
|
|
Blood pressure
|
Systolic ≥130 or diastolic ≥85 mmHg
|
Systolic ≥130 or diastolic ≥85 mmHg or treatment of previously diagnosed hypertension
|
|
|
Triglycerides
|
≥1.7mmol/L (≥150 mg/dL)
|
≥1.7mmol/l (≥150 mg/dL)or specific treatment for high triglycerides
|
|
|
HDL-C
|
< 1.03 mmol/L (<40 mg/dL)
|
< 1.03 mmol/L (<40 mg/dL) in male and 1.29 mmol/L (<50 mg/dL) in females or specific treatment for low HDL-C
|
|
|
Fasting glucose
|
5.6 mmol/l (100 mg/dL)
|
5.6 mmol/l (100 mg/dL) or known T2DM
|
|